SCHEMBL18629883

SCHEMBL18629883

CC(=O)c1cc(C)c(O)c(C#N)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA5A P35218 1/20 0.42
KDM4E B2RXH2 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LMNA P02545 1/20 0.40
CYP2C9 P11712 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
SLC22A12 Q96S37 1/20 0.35
EGFR P00533 1/20 0.35
ERBB2 P04626 1/20 0.35
ALDH1A1 P00352 2/20 0.35
GAA P10253 1/20 0.35
S1PR3 Q99500 1/20 0.35
HSD17B1 P14061 1/20 0.34
MEN1 O00255 1/20 0.34
MAPK1 P28482 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7369949 0.83 CA5A (0.43) CA5AKDM4ESMN1; SMN2LMNACYP2C9
SCHEMBL31520153 0.81 KDM4E (0.50) KDM4ELMNACYP2C9L3MBTL1ALDH1A1
SCHEMBL32669678 0.81 KDM4E (0.50) KDM4ELMNACYP2C9L3MBTL1ALDH1A1
SCHEMBL23317588 0.80 CYP11B1 (0.41) CA5AKDM4ESMN1; SMN2CYP2C9L3MBTL1
SCHEMBL22230775 0.80 TTR (0.42) CA5AKDM4ESMN1; SMN2LMNACYP2C9
SCHEMBL18629884 0.80 GSK3B (0.45) CYP2C9ALDH1A1MEN1KMT2A
SCHEMBL1644952 0.80 CA5A (0.56) CA5ASMN1; SMN2LMNACYP2C9ALDH1A1
SCHEMBL7662707 0.76 VNN1 (0.45) KDM4ESMN1; SMN2CYP11B1CYP11B2ALDH1A1
SCHEMBL2369495 0.76 S1PR3 (0.51) CYP11B1CYP11B2ALDH1A1S1PR3MEN1
SCHEMBL30737737 0.76 S1PR3 (0.51) CYP11B1CYP11B2ALDH1A1S1PR3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3348557-B1 IMIDAZO[1,2A]PYRIDINES FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2020-04-29 EP disclosed
EP-3348557-B1 IMIDAZO[1,2A]PYRIDINES FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2020-04-29 EP disclosed
US-10399971-B2 Compound for treating or preventing hyperuricemia or gout JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2019-09-03 US disclosed
US-10399971-B2 Compound for treating or preventing hyperuricemia or gout JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2019-09-03 US disclosed
US-20180282321-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2018-10-04 US disclosed
EP-3348557-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd (CN) 2018-07-18 EP disclosed
EP-3348557-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd (CN) 2018-07-18 EP disclosed
WO-2017041732-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT 江苏新元素医药科技有限公司 2017-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180282321-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT SLC10A1, SLC5A1, SLC10A6 CA5A 1148/4885KDM4E 2487/4885SMN1; SMN2 3361/4885
US-10399971-B2 Compound for treating or preventing hyperuricemia or gout SLC10A1, SLC5A1, SLC10A6 CA5A 1148/4885KDM4E 2487/4885SMN1; SMN2 3361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.